Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin.

Trial Profile

Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs Exenatide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2011 Planned End Date changed from 1 Oct 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 13 Dec 2010 Planned end date changed from 1 Oct 2010 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top